HUMIRA(R) (Adalimumab) Receives FDA Approval For Treatment Of Crohn's DiseaseAbbott announced today it has received U.S. Food and Drug Administration (FDA) approval to market HUMIRA(R) (adalimumab) as a treatment for reducing the signs and symptoms and inducing and maintaining clinical remission in adults with moderately to severely active Crohn's disease who have had an inadequate response to conventional therapy. [click link for full article]
Ocera Therapeutics Initiates A Phase 2 Trial For Active PouchitisOcera Therapeutics Inc. announced today that a Phase 2 exploratory study for AST-120 in patients with active pouchitis was initiated at Cleveland Clinic and that it has also met the 50 percent enrollment target in its pivotal Phase 3 trial of AST-120 in fistulizing Crohn's disease. The Phase 2 exploratory study will be conducted by Bo Shen, M.D. at Cleveland Clinic and will evaluate the efficacy and safety of AST-120. In addition, Ocera's President and CEO, Laurent Fischer, M. [click link for full article]
An Important New Clue In Susceptibility To Crohn's DiseaseCrohn's disease is a chronic relapsing inflammatory disorder of the intestinal tract that affects an estimated 0.15% of people in the developed world. Common symptoms include abdominal pain and diarrhea, but the disorder is often associated with debilitating clinical complications. Researchers from the University of Liege, Belgium, have now uncovered an important clue to the susceptibility of individuals to this disease. [click link for full article]
ECP May Be Effective In Treating Crohn's DiseaseResults from an international multi-center Phase II clinical trial suggest that extracorporeal photopheresis (ECP) may be effective in treating patients with clinically active (OR symptomatic) Crohn's disease who cannot tolerate or are refractory to immunosuppressants and/or anti-TNF agents. [click link for full article]
|